MSD’s Keytruda backed for bladder cancer
European regulators have backed expanding approval of MSD’s immunotherapy Keytruda to include the treatment of locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.
Read More
Tag: metastatic urothelial carcinoma
EU approves Opdivo for bladder cancer
Bristol-Myers Squibb’s Opdivo has picked up approval for its eighth indication in Europe, having won clearance for the treatment of a subset of patients with metastatic urothelial carcinoma (mUC).
Read More
AZ’ Imfinzi gets accelerated nod for bladder cancer
AstraZeneca has secured accelerated approval in the US for its immunotherapy Imfinzi as a treatment for certain patients with advanced bladder cancer.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
